- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00162682
Monitoring Highly Active Antiretroviral Therapy in HIV-infected Parents in Thailand
A Phase III, Randomized, Non-inferiority Trial Comparing the Standard Viral Load Based Antiretroviral Monitoring Strategy With a CD4 Based Monitoring Strategy Among Antiretroviral Naive Immunocompromised Adults in Thailand
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Implementation of highly active antiretroviral therapy (HAART) has led to a substantial decrease in HIV-related mortality and morbidity. Current guidelines emphasize maximal and durable viral load suppression. However, while the goal of therapy is the restoration of immunity, treatment failure is usually defined as the inability to maintain undetectable viral load, without regard to immune function. This situation often leads to a rapid sequence of therapeutic switches, thus narrowing therapeutic options over time. A monitoring strategy driven primarily by the patient's immune restoration would most likely be as effective in preventing disease progression, would lead to fewer changes in HAART regimens and would be considerably simpler and cost effective.
Subjects will be randomly assigned to one of two switching strategies:
- VL-S, the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
- CD4-S, the alternative CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
The initial HAART regimen will be a NNRTI+NRTI containing regimen and the second line regimen will be a PI containing regimen, subsequent regimens will be chosen individually based on tolerance, previous drugs used, resistance profile, and drugs available. Patients will be followed until the end of the study (maximum of 5 years for the first enrollee, three years for the last enrollee).
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Bangkok, Thaïlande, 10220
- Buddhachinaraj Hospital
-
Chacheongsao, Thaïlande, 24000
- Chacheongsao Hospital
-
Khon Kaen, Thaïlande, 40000
- Regional Health Promotion Centre 6,
-
Rayong, Thaïlande, 21000
- Rayong Hospital
-
Samutprakarn, Thaïlande, 10280
- Samutprakarn Hospital
-
-
Chantaburi
-
Prapokklao, Muang, Chantaburi, Thaïlande, 22000
- Prapokklao Hospital
-
-
Chiang Mai
-
Mae Rim, Chiang Mai, Thaïlande, 50180
- Nakornping Hospital
-
Sanpatong, Chiang Mai, Thaïlande, 50120
- Sanpatong Hospital
-
-
Chiang Rai
-
Mae Chan, Chiang Rai, Thaïlande, 57110
- Mae Chan Hospital
-
-
Chiangrai
-
Muang, Chiangrai, Chiangrai, Thaïlande, 57000
- Chiangrai Prachanukroh Hospital
-
-
Chonburi
-
Muang, Chonburi, Chonburi, Thaïlande, 20000
- Chonburi Hospital
-
-
Lampang
-
Muang, Lampang, Lampang, Thaïlande, 52000
- Lampang Hospital
-
-
Lamphun
-
Muang, Lamphun, Thaïlande, 51000
- Lamphun Hospital
-
-
Mahasarakam
-
Muang, Mahasarakam, Thaïlande, 44000
- Mahasarakam Hospital
-
-
Nakornratchasrima
-
Muang, Nakornratchasrima, Nakornratchasrima, Thaïlande, 30000
- Maharaj Nakornratchasrima Hospital
-
-
Nong Khai
-
Muang, Nong Khai, Nong Khai, Thaïlande, 43000
- Nong Khai Hospital
-
-
Phayao
-
Muang, Phayao, Thaïlande, 56000
- Phayao Provincial Hospital
-
-
Ratchaburi
-
Muang, Ratchaburi, Ratchaburi, Thaïlande, 70000
- Ratchaburi Hospital
-
-
Samutsakorn
-
Muang, Samutsakorn, Samutsakorn, Thaïlande, 74000
- Samutsakorn Hospital
-
-
Songkla
-
Hat Yai, Songkla, Thaïlande, 90110
- Hat Yai Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Eligibility Criteria:
Patients fulfilling the following criteria are eligible:
- At least 18 years of age
- Confirmed HIV infection: two positive serology results from two different blood draws are required for documentation of HIV infection.
- Antiretroviral drug naïve with the exception of short course of antiretrovirals received in the context of the prevention of mother to child HIV transmission
- Need for antiretroviral treatment
- Willingness to receive a long-term treatment for the HIV infection, according to the study schedule at the participating site
- Signed informed consent to participate in the study (the patient's legal guardian may give his/her consent if the patient cannot provide consent)
- Does not present an exclusion criteria to the knowledge of the site investigator
Inclusion Criteria:
Eligible patients fulfilling the following criteria can be enrolled in the study:
- Meeting all eligibility criteria
- Two CD4+ cell counts between 50 and 250 cells/mm3 performed within the last six months before enrolment (CD4 cell count should be assessed at least 2 weeks apart from any acute infection)
- Willingness to modify antiretroviral therapy in accordance with the randomized switching scheme assignment
- Subject understands that study drugs will be supplied for free by the study only during participation in the study. After discontinuation of the study, patients will be taken care of in the National ARV Access Program.
Exclusion Criteria:
- For women, pregnancy
- For women of child bearing potential, lack of willingness to follow an effective method of contraception (in case, during the study, a woman wants to become pregnant or becomes pregnant, she should inform the physician immediately for best therapeutic decision)
- Chronic hepatitis B or C
- Acute hepatitis within 30 days of study entry.
- Acute HIV infection, as it can be established with the date of last negative serology less than one year before enrollment and the history of the patient disease
- Co-enrollment in another study without prior written agreement of the study team
- Psycho-social environment or condition which, in the physician's opinion, makes adherence to the protocol highly unlikely.
- Pre-existing diabetes mellitus (prior gestational diabetes is allowed).
- The following laboratory values: hemoglobin < 8.0 mg/dl, absolute neutrophil count < 1000 cells/mm3, ALT, AST or total bilirubin value > 5.0 x ULN, serum creatinine > 1.0 x ULN, platelet count < 50,000/mm3, pancreatic amylase >2.0 x ULN or lipase > 2.0 X ULN, or total amylase > 2.0 X ULN plus symptoms of pancreatitis.
- Severe illness, grade 3 or 4 laboratory exam values not resolved within one month of enrollment without previous agreement of the PHPT attending physician
- Any clinically significant condition (other than HIV infection) which, in the investigator's opinion, would interfere with the conduct of the study.
- Current active substance or alcohol abuse that would interfere with participation in the study.
- Condition(s) that contraindicate all the first line regimens proposed in this study.
- Chemotherapy for active malignancy.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur actif: 1
* VL-S, the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
|
Antiretroviral treatment will use the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
Antiretroviral treatment is monitored using a CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
|
Expérimental: 2
CD4-S, the alternative CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
|
Antiretroviral treatment will use the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
Antiretroviral treatment is monitored using a CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Proportion of "clinical failures" defined as confirmed CD4 count below 50/mm3, first or new AIDS-defining event, or death
Délai: After 3 years of follow-up
|
After 3 years of follow-up
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
The number of therapeutic options left taking into account drugs exhausted cross-resistance mutations and shared toxicities
Délai: After 3 years of follow-up
|
After 3 years of follow-up
|
The secondary endpoint related to safety will be time to the first development of grade 3 or grade 4 sign, symptom, and laboratory abnormality.
Délai: During 3 years of follow-up
|
During 3 years of follow-up
|
Collaborateurs et enquêteurs
Collaborateurs
Les enquêteurs
- Chercheur principal: Marc Lallemant, MD, Institut de Recherche pour le Developpement & Harvard School of Public Health
Publications et liens utiles
Publications générales
- Jourdain G, Ngo-Giang-Huong Nicole, Le Coeur S, Traisaithit P, Barbier S, Techapornroong M, Banchongkit S, Buranabanjasatean S, Halue G, Lallemant M, and The PHPT-3 study group. PHPT-3: A Randomized Clinical Trial Comparing CD4 versus Viral Load (VL) Antiretroviral Therapy Monitoring/Switching Strategies in Thailand. 18th Conference on Retroviruses and Opportunistic Infections, 27 February-2 March, 2011,Boston, USA. Oral Presentation #44.
- Cressey TR, Urien S, Hirt D, Halue G, Techapornroong M, Bowonwatanuwong C, Leenasirimakul P, Treluyer JM, Jourdain G, Lallemant M; PHPT-3 Team. Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir. Ther Drug Monit. 2011 Feb;33(1):25-31. doi: 10.1097/FTD.0b013e3182057f6f.
- Jourdain G, Le Coeur S, Ngo-Giang-Huong N, Traisathit P, Cressey TR, Fregonese F, Leurent B, Collins IJ, Techapornroong M, Banchongkit S, Buranabanjasatean S, Halue G, Nilmanat A, Luekamlung N, Klinbuayaem V, Chutanunta A, Kantipong P, Bowonwatanuwong C, Lertkoonalak R, Leenasirimakul P, Tansuphasawasdikul S, Sang-A-Gad P, Pathipvanich P, Thongbuaban S, Wittayapraparat P, Eiamsirikit N, Buranawanitchakorn Y, Yutthakasemsunt N, Winiyakul N, Decker L, Barbier S, Koetsawang S, Sirirungsi W, McIntosh K, Thanprasertsuk S, Lallemant M; PHPT-3 study team. Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand. PLoS Med. 2013 Aug;10(8):e1001494. doi: 10.1371/journal.pmed.1001494. Epub 2013 Aug 6.
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Infections par virus à ARN
- Maladies virales
- Infections
- Infections transmissibles par le sang
- Maladies transmissibles
- Maladies sexuellement transmissibles, virales
- Maladies sexuellement transmissibles
- Infections à lentivirus
- Infections à rétroviridae
- Syndromes d'immunodéficience
- Maladies du système immunitaire
- Infections à VIH
- Agents anti-infectieux
- Agents antiviraux
- Agents antirétroviraux
Autres numéros d'identification d'étude
- R01HD042964 (Subvention/contrat des NIH des États-Unis)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Infections à VIH
-
Icahn School of Medicine at Mount SinaiIRRASRecrutementHémorragie intraventriculaire (HIV)États-Unis
-
Yale UniversityComplétéPrématurité | Nourrissons de très faible poids à la naissance | Hémorragie intraventriculaire (HIV) | Saignement dans le cerveauÉtats-Unis
-
West Virginia UniversityInscription sur invitationInfection de la peau et des tissus mous | Infection gastro-intestinale | Infection pulmonaire | Infection des os et des articulations | Infection endovasculaire | Infection génito-urinaireÉtats-Unis
-
Taipei Medical University WanFang HospitalInconnue
-
Ondine Biomedical Inc.ComplétéInfection du site opératoire | Infection nosocomiale | Infection associée aux soins de santéÉtats-Unis
-
Croydon Health Services NHS TrustComplétéInfection du site opératoire | Infection de la plaie | Césarienne; Infection | Infection périnéaleRoyaume-Uni
-
Leiden University Medical CenterRadboud University Medical Center; University Medical Center Groningen; Erasmus... et autres collaborateursRecrutementInfection prothétique-articulaire | Infection de la hanche | Infection; Genou, ArticulationPays-Bas
-
Cairo UniversityRecrutementInfection postopératoire | Complications de la césarienne | Infection vaginaleEgypte
-
Angela BiancoStryker NordicRésiliéCésarienne | Infection du site opératoire | Infection nosocomialeÉtats-Unis
-
Gundersen Lutheran Medical FoundationGundersen Lutheran Health SystemComplétéInfection du site opératoire | Infection superficielle du site opératoire | Infection profonde du site chirurgical | Infection du site chirurgical d'un organe/de l'espaceÉtats-Unis